Compile Data Set for Download or QSAR
maximum 50k data
Report error Found 145 Enz. Inhib. hit(s) with all data for entry = 11474
TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465216(US10793564, Compound 5 | US10793564, Compound 55 |...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465218(US10793564, Compound 7 | US11419869, Compound 7 | ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465221(US10793564, Compound 10 | US11419869, Compound 10 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465222(US10793564, Compound 11 | US11419869, Compound 11 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465223(US10793564, Compound 12 | US11419869, Compound 12 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465225(US10793564, Compound 14 | US11419869, Compound 14 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465226(US10793564, Compound 15 | US11419869, Compound 15 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465222(US10793564, Compound 11 | US11419869, Compound 11 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM618982(US20230293519, Compound 17)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465229(US10793564, Compound 18 | US11419869, Compound 18 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465230(US10793564, Compound 19 | US11419869, Compound 19 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465231(US10793564, Compound 20 | US11419869, Compound 20 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465232(US10793564, Compound 21 | US11419869, Compound 21 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465233(US10793564, Compound 22 | US11419869, Compound 22 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465234(US10793564, Compound 23 | US11419869, Compound 23 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465235(US10793564, Compound 24 | US11419869, Compound 24 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465236(US10793564, Compound 25 | US11419869, Compound 25 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465237(US10793564, Compound 26 | US11419869, Compound 26 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465238(US10793564, Compound 27 | US11419869, Compound 27 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465239(US10793564, Compound 28 | US11419869, Compound 28 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465240(US10793564, Compound 29 | US11419869, Compound 29 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465241(US10793564, Compound 30 | US11419869, Compound 30 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465242(US10793564, Compound 31 | US11419869, Compound 31 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465243(US10793564, Compound 32 | US11419869, Compound 32 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465244(US10793564, Compound 33 | US11419869, Compound 33 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465246(US10793564, Compound 35 | US11419869, Compound 35 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465249(US10793564, Compound 38 | US11419869, Compound 38 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465250(US10793564, Compound 39 | US11419869, Compound 39 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465251(US10793564, Compound 40 | US11419869, Compound 40 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465252(US10793564, Compound 41 | US11419869, Compound 41 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465253(US10793564, Compound 42 | US11419869, Compound 42 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465254(US10793564, Compound 43 | US11419869, Compound 43 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465255(US10793564, Compound 44 | US11419869, Compound 44 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465256(US10793564, Compound 45 | US11419869, Compound 45 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465257(US10793564, Compound 46 | US11419869, Compound 46 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465258(US10793564, Compound 47 | US11419869, Compound 47 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465259(US10793564, Compound 48 | US11419869, Compound 48 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465260(US10793564, Compound 49 | US11419869, Compound 49 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465261(US10793564, Compound 50 | US11419869, Compound 50 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465262(US10793564, Compound 51 | US11419869, Compound 51 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465265(US10793564, Compound 54 | US11419869, Compound 54 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465264(US10793564, Compound 53 | US11419869, Compound 53 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465265(US10793564, Compound 54 | US11419869, Compound 54 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM566504((S)-4-((2-ethoxyethyl) (4-(5,6,7,8-tetrahydro-1,8-...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM619021(US20230293519, Compound 56)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465268(US10793564, Compound 57 | US11419869, Compound 57 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465269(US10793564, Compound 58 | US11419869, Compound 58 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465270(US10793564, Compound 59 | US11419869, Compound 59 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465271(US10793564, Compound 60 | US11419869, Compound 60 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM465272(US10793564, Compound 61 | US11419869, Compound 61 ...)
Affinity DataIC50: <50nMAssay Description:Microplates were coated with recombinant human integrin alphavbeta6 (2 ug/mL) in PBS (100 uL/well 25 C., overnight). The coating solution was removed...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


Displayed 1 to 50 (of 145 total ) | Next | Last >>
Jump to: